Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:05:57.697Z.
Calculation as of: 2026-10-06T17:05:57.697Z.
Quote observation: 2026-10-06T17:01:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe921af54d6420969180622b7fbdd7ef934f73e64ffcc47ddb287d73eacb5931
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$11.12M
EBITDA Yield
N/A
TTM Avg
41.52%
3Y Avg
41.52%
5Y Avg
41.52%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioVie Inc. (BIVI) | $11.12M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | N/A | 41.52% | 41.52% | 41.52% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.24M | N/A | N/A | N/A | N/A |
| Pluri Inc. (PLUR)vs › | $11.11M | N/A | 0.09% | 0.09% | 0.09% |
| Caring Brands, Inc. (CABR)vs › | $10.96M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.88M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.39M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.56M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.63M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
